TERB2

Across TCGA pan-cancer cohorts, TERB2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TERB2 data layer compared with 13 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher TERB2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TERB2 expression acts as an unfavorable survival marker.

DLBC, SKCM, and UCEC are the cancer types where TERB2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
GBM	OS	Median	All	0.121	0.415	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TERB2–DLBC (OS)

Open the DLBC breakdown →